Cyclic Heavy Menstrual Bleeding Global Market Report 2024

The global cyclic heavy menstrual bleeding market has grown strongly in recent years. It will grow from $40.21 billion in 2023 to $42.97 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to aging population, raise awareness about menstrual health, rising disposable incomes, government initiatives.

The global cyclic heavy menstrual bleeding market is expected to see strong growth in the next few years. It will grow to $54.27 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing female population, rising prevalence of obesity, increasing access to healthcare, growing popularity of biosimilars, increasing demand for preventive treatments. Major trends in the forecast period include medical advancements, minimally invasive procedures, nutritional approaches, eco-friendly menstrual products.

The escalating incidence of uterine fibroids and polyps is anticipated to serve as a catalyst for the expansion of the cyclic heavy menstrual bleeding market in the foreseeable future. Uterine fibroids and uterine polyps are common noncancerous growths that can develop within the uterus (womb) of women. Treatment for these conditions plays a pivotal role in reducing blood loss, regulating the menstrual cycle, preventing complications, and improving the emotional well-being of individuals grappling with menstrual disorders. For instance, as of March 2022, data published in Frontiers, a journal based in Switzerland, reported the results of a survey conducted in the United States among 1,346 randomly selected women aged 35 to 49. The survey, which relied on self-reporting, revealed a 60% incidence of uterine fibroids by age 35 among African-American women, which increased to over 80% by age 50. In contrast, Caucasian women in the same study exhibited an incidence of 40% by age 35, escalating to nearly 70% by age 50. Hence, the increasing prevalence of uterine fibroids and polyps is a driving force behind the growth of the cyclic heavy menstrual bleeding market.

The increasing awareness regarding menstrual health and the implementation of government initiatives are poised to act as driving forces for the growth of the cyclic heavy menstrual bleeding market in the foreseeable future. Menstrual health awareness encompasses the knowledge, understanding, and acknowledgment of various aspects related to the menstrual cycle, reproductive health, and the physical and emotional well-being of individuals experiencing menstruation. It aims to address social taboos, dispel myths and misconceptions surrounding menstruation, and empower individuals to manage their menstrual health confidently, with dignity, and access to essential resources. For instance, as of May 2022, the World Bank, a US-based financial institution, reported that the government of Ghana introduced The GAMA Sanitation and Water Project. This initiative included a comprehensive qualitative study to explore the effects of Menstrual Health Management (MHM) interventions in schools on the educational engagement of adolescent girls. The project involved the construction of sanitation facilities in over 260 schools throughout the Greater Accra Metropolitan Area. These facilities featured separate and secure toilets and changing rooms for girls, equipped with locks on doors, hygienic and safe disposal areas for used sanitary products, and handwashing facilities. Consequently, the rising awareness of menstrual health and government initiatives are key drivers behind the growth of the cyclic heavy menstrual bleeding market.

The growth of the heavy menstrual bleeding market is being impeded during the forecast period due to the increasing costs associated with research and development. The development of novel treatments, medications, and medical devices for managing heavy menstrual bleeding entails substantial investments in research and development. These expenses can pose a financial challenge for pharmaceutical and medical device companies, leading to a degree of hesitancy in the pursuit of innovative solutions. For example, as of September 2023, data from the House of Commons, a governmental institution based in the United Kingdom, revealed that the overall gross expenditure on research and development in the UK had risen to $80.91 billion in 2021, up from $75.17 billion in 2020. Hence, the mounting research and development costs represent a limiting factor in the growth of the heavy menstrual bleeding market.

The prominent companies in the cyclic heavy menstrual bleeding market are focused on the development of innovative medications like MYFEMBREE to gain a competitive edge in the industry. In a notable development, in May 2021, Myovant Sciences, a pharmaceutical company headquartered in the United States, in collaboration with Pfizer, another US-based pharmaceutical company, unveiled MYFEMBREE. This groundbreaking introduction received approval from the Food and Drug Administration (FDA), a US government agency. MYFEMBREE represents the first-ever once-daily treatment designed for the management of heavy menstrual bleeding linked to uterine fibroids in premenopausal women. Its treatment duration extends up to 24 months. Notably, this medication not only addresses heavy menstrual bleeding but also mitigates the risk of bone loss. It incorporates norethindrone acetate, a progestin, which is a crucial component when estrogen is prescribed to women with a uterus (womb). This innovative treatment marks a significant advancement in addressing heavy menstrual bleeding.

In October 2022, Unified Women's Healthcare, a healthcare company based in the United States specializing in women's healthcare treatment, completed the acquisition of Gennev for an undisclosed sum. This strategic move by Unified Women's Healthcare is aimed at enhancing its women's healthcare portfolio to offer improved healthcare outcomes and a superior patient experience across all stages of a woman's healthcare journey. Gennev, also based in the United States, is a company dedicated to providing feminine care services, offering a range of treatments that empower women to actively manage their health during and after menopause. This acquisition serves as a pivotal step in strengthening women's healthcare services.

Major players in the cyclic heavy menstrual bleeding market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Reckitt Benckiser Group Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the cyclic menstrual bleeding market in 2023. The regions covered in cyclic heavy menstrual bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cyclic heavy menstrual bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of cyclic heavy menstrual bleeding include polymenorrhea, oligomenorrhea, and metrorrhagia. Polymenorrhea is a medical term used to describe menstrual cycle irregularities where a woman experiences menstrual periods more frequently than the typical cycle length of approximately 21 to 35 days. Treatment options encompass medications, hormonal therapy, and surgical procedures, with various methods of administration such as oral and parenteral. These treatments are utilized by diverse end-users, including hospitals, home-based care, specialty clinics, and others.

This report provides cyclic heavy menstrual bleeding market statistics, including cyclic heavy menstrual bleeding industry global market size, regional shares, competitors with a cyclic heavy menstrual bleeding market share, detailed cyclic heavy menstrual bleeding market segments, market trends and opportunities and any further data you may need to thrive in the cyclic heavy menstrual bleeding industry. This cyclic heavy menstrual bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cyclic heavy menstrual bleeding market consists of revenues earned by entities by provide diagnostic testing, treatment planning and non-hormonal medications. The market value includes the value of related goods sold by the service provider or included within the service offering. The cyclic heavy menstrual bleeding market also includes sales of sanitary products, hormonal contraceptives, tranexamic acid and nonsteroidal anti-inflammatory drugs (NSAIDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.